Latest Clinical News

Immunotherapy Benefits Patients with Drug-Resistant Multiple Myeloma (09-2-2015)

In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana-Farber Cancer Institute and other organizations... Continue Reading

Women with Early Breast Cancer Have Fewer Side Effects with Shorter Courses of Radiation (09-1-2015)

Women with early breast cancer have fewer side effects when they’re treated with shorter courses of radiation at higher doses than with conventional radiation to the whole breast. These findings were reported in JAMA Oncology.[1] Treatment with shorter... Continue Reading

High Use of Alternative Medicine in Senior Cancer Patients (08-31-2015)

(PHILADELPHIA) — Alternative medicines are widely thought to be at least harmless and very often helpful for a wide range of discomforts and illnesses. However, although they’re marketed as “natural,” they often contain active ingredients... Continue Reading

Breast Cancer Research and Treatment Publishes Oncotype DX(R) DCIS Score(TM) Study Conducted in Canada (08-27-2015)

Genomic Health, Inc. (Nasdaq: GHDX) announced that Breast Cancer Research and Treatment published results from a second large clinical validation study of Oncotype DX® in patients with stage 0 breast cancer, also known as DCIS (Ductal Carcinoma In Situ).... Continue Reading

Patients Rising, Launched to Fight for Access to Vital Therapies and Services for Patients with Life-Threatening Diseases (08-25-2015)

Patient advocacy veterans Jonathan and Terry Wilcox today announced the launch of a new not-for-profit organization, Patients Rising. This patient advocacy organization will educate, advocate and communicate the importance of access to vital therapies... Continue Reading

Understanding Precision Cancer Medicine (08-25-2015)

Precision cancer medicine is an evolving concept in cancer care that aims to leverage new genomic information about a specific cancer to more precisely target treatment. Precision medicine seeks to define the genomic alterations that are driving a specific... Continue Reading

XBiotech Completes Enrollment for Xilonix™ Phase III Registration Study in Europe, US Trial Ongoing (08-24-2015)

XBiotech has announced that it has completed enrollment of the Company’s pivotal, randomized double-blinded placebo controlled Phase III study in Europe of Xilonix™ for the treatment of advanced colorectal cancer. The US based trial is ongoing at... Continue Reading

Two-drug combination boosts survival in metastatic prostate cancer (08-17-2015)

Newly diagnosed patients with metastatic, hormone-sensitive prostate cancer gained a dramatic survival benefit when started on two drugs simultaneously, rather than delaying the second drug until the cancer began to worsen, according to results of a clinical... Continue Reading

Food and Drug Administration approves Odomzo for treatment of basal cell carcinoma (08-13-2015)

The U. S. Food and Drug Administration approved Odomzo® (sonidegib, formerly LDE225) for the treatment of patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates... Continue Reading

FDA Designates Breakthrough Therapy Designation for Azedra in Pheochromocytoma and Paraganglioma (08-12-2015)

The U.S. Food and Drug Administration (FDA) has designated Azedra as a Breakthrough Therapy for the treatment of patients with iobenguane-avid metastatic or recurrent pheochromocytoma and paraganglioma. Azedra is currently being evaluated in a pivotal... Continue Reading

Vectibix® Improves Survival in Patients with Wild-Type KRAS Metastatic Colorectal Cancer after Progression on Chemotherapy (08-11-2015)

  Vectibix® (panitumumab) appears to improve overall survival among patients with wild-type KRAS metastatic colorectal cancer that has progressed on or following chemotherapy. A Phase III trial of Vectibix is currently underway, but researchers... Continue Reading

Afinitor® Promising in Neuroendocrine Tumors Originating in Gastrointestinal Tract or Lungs (08-10-2015)

The drug Afinitor® (everolimus) is currently be studied in a Phase III clinical trial for patients with nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract or lungs. The trial is ongoing, but findings so far are promising: patients... Continue Reading

Next Page »